EC
RUBY

Euclidean Capital’s Rubius Therapeutics, Inc RUBY Stock Holding History

Euclidean Capital’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,791
Closed -$339K – 15
2021
Q1 		$339K Buy
+12,791
New +$187K 0.11% 13

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Euclidean Capital's RUBY Position: Q2 2021 in Review

Euclidean Capital sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2021, closing a stake of 12,791 shares — an estimated $339K sold.

Euclidean Capital first reported a position in RUBY in Q1 2021 and held it in 1 quarter. The position peaked at $339K in Q1 2021. 108 funds tracked by Wall St. Rank hold RUBY as of Q2 2021.

  • Euclidean Capital reported no remaining Rubius Therapeutics, Inc position as of Q2 2021 after selling out during the quarter.
  • Euclidean Capital sold 12,791 Rubius Therapeutics, Inc shares in Q2 2021, an estimated $339K.
  • Euclidean Capital first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 1 quarter.
  • Euclidean Capital's Rubius Therapeutics, Inc position peaked at $339K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2021.

Based on Euclidean Capital's 13F filing for Q2 2021, filed 16 Aug 2021.